Skip to content
ClinCalc Pro
Menu
Aminopenicillin Antibiotic Pregnancy: eMC §4.6, verbatim: 'Animal studies with Ampicillin have shown no teratogenic effects. The product has been in extensive clinical use since 1961 and its use in human pregnancy has been well documented in clinical studies. When antibiotic therapy is required during pregnancy, Ampicillin may be considered appropriate.' Breast-feeding: 'During lactation, trace quantities of penicillins can be detected in breast milk. Adequate human and animal data on use of Ampicillin during lactation are not available.'

Ampicillin

Brand names: Penbritin

Ampicillin is a broad-spectrum aminopenicillin antibiotic used for susceptible infections including certain respiratory, urinary, gastrointestinal and listerial infections.

Adult dose

Dose: Septicaemia, endocarditis, osteomyelitis: 500 mg four to six times a day IM or IV for one to six weeks. Peritonitis, intra-abdominal sepsis: 500 mg four times a day IM or IV. Meningitis: 2 g six-hourly IV
Route: Intramuscular or intravenous injection/infusion
Frequency: Four to six times a day (six-hourly for meningitis)
SCOPE - READ FIRST: this covers the PARENTERAL (IM/IV) route only, which is this page's primary route in current UK practice - the page itself records that ampicillin has been superseded by amoxicillin for most oral indications while intravenous ampicillin remains important for listeria meningitis, enterococcal endocarditis and group B streptococcal infection. The only UK source in this bundle is the injection SPC, which contains NO oral posology, so no oral dose has been drafted; take the oral dose from the SPC of the specific oral product. TABLE-FLATTENING CAVEAT: the SPC's indication/dose table arrived flattened in the fetched text as 'Usual adult dosage (including elderly patients): Septicaemia, endocarditis, osteomyelitis: Peritonitis, intra-abdominal sepsis: Meningitis: 500 mg four to six times a day IM or IV for one to six weeks. 500mg four times a day IM or IV. Adult dosage: 2 g six-hourly IV. Children dosage: 150 mg/kg daily IV in divided doses.' Every number above is verbatim; the pairing of each indication with its dose follows the order in which the two lists appear and should be confirmed against the SPC itself before use. THE US SOURCE IS A DIFFERENT PRODUCT: the openFDA record is for AMPICILLIN AND SULBACTAM (Meitheal Pharmaceuticals, 2025-07-22), whose '1.5 g to 3 g every six hours' figures are ampicillin PLUS sulbactam totals (1 g ampicillin/0.5 g sulbactam to 2 g ampicillin/1 g sulbactam); none of it has been used for dosing here. OTHER ROUTES (eMC §4.2, 'in conjunction with systemic therapy'): intraperitoneal 500 mg daily in up to 10 ml water for injections; intrapleural 500 mg daily in 5-10 ml water for injections; intra-articular 500 mg daily in up to 5 ml water for injections or sterile 0.5% procaine hydrochloride solution; local use in abdominal surgery, 1 g sterile powder sprinkled into the wound extraperitoneally or into muscle layers to prevent wound infection post operatively. NO MAXIMUM ENTERED: the SPC states 'All recommended dosages are a guide only. In severe infections the above dosages may be increased', so it sets no ceiling; the US label's 'total dose of sulbactam should not exceed 4 grams per day' is a ceiling for the other component of a different product and has not been carried over. RECONSTITUTION AND METHOD (eMC §4.2): intramuscular - 'Add 1.5 ml water for injections to 500mg vial contents'; intravenous - 'Dissolve 500 mg in 10 ml water for injections. Administer by slow injection (three to four minutes). Ampicillin may also be added to infusion fluids or injected, suitably diluted, into the drip tube over a period of three to four minutes.' SODIUM: 'This medicine contains 33.7 mg of sodium per vial, equivalent to 1.7% of the WHO recommended maximum daily intake of 2 g sodium for an adult.'

Paediatric dose

Dose: 150 mg/kg/day
Route: Intravenous
Frequency: Daily in divided doses
Concentration: 50 mg/ml
eMC §4.2, verbatim: 'Children dosage: 150 mg/kg daily IV in divided doses.' This figure sits in the MENINGITIS row of the SPC's dose table and should be treated as the meningitis dose rather than a general paediatric dose - see the table-flattening caveat in the adult notes. For routine (non-meningitis) paediatric dosing the SPC gives a fraction rule, not a per-kg rule: 'Half adult routine dosage for children under 10 years' - which cannot be expressed as a per-kg figure and so is recorded here only. No neonatal dose, no number of divided doses per day, no dose interval and no paediatric maximum are given anywhere in this bundle, and no age band is attached to the 150 mg/kg/day figure. CONCENTRATION: 50 mg/mL is the intravenous reconstitution from the SPC method of administration ('Dissolve 500 mg in 10 ml water for injections'); the intramuscular reconstitution is different (add 1.5 ml water for injections to a 500 mg vial), so this concentration applies to the IV route only. The US source in this bundle is ampicillin WITH SULBACTAM and its 300 mg/kg/day paediatric figure is a combination total (200 mg ampicillin plus 100 mg sulbactam per kg per day) - it has not been used here. Verify the paediatric dose, the dosing interval and any neonatal dose against a children's formulary.

Dose adjustments

Renal

eMC §4.2, verbatim: 'In the presence of severe renal impairment (creatinine clearance 10ml/min) a reduction in dose or extension of dose interval should be considered. In cases of dialysis, an additional dose should be administered after the procedure.' The comparator symbol before '10ml/min' is missing from the fetched text (it reads as a bare '10ml/min'), so read the threshold from the SPC itself before applying it. No numeric replacement regimen is given. §4.4 repeats that 'Dosage should be adjusted in patients with renal impairment'. The creatinine-clearance dosing table in the US source belongs to ampicillin WITH sulbactam and has not been carried over.

Hepatic

No hepatic dose adjustment is given in this bundle. eMC §4.8 records that, as with other beta-lactam antibiotics, hepatitis and cholestatic jaundice have been reported rarely and a moderate and transient increase in transaminases has been reported. (The US contraindication for previous cholestatic jaundice/hepatic dysfunction relates to ampicillin with sulbactam, a different product.)

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

eMC §4.2, verbatim: 'Children dosage: 150 mg/kg daily IV in divided doses.' This figure sits in the MENINGITIS row of the SPC's dose table and should be treated as the meningitis dose rather than a general paediatric dose - see the table-flattening caveat in the adult notes. For routine (non-meningitis) paediatric dosing the SPC gives a fraction rule, not a per-kg rule: 'Half adult routine dosage for children under 10 years' - which cannot be expressed as a per-kg figure and so is recorded here only. No neonatal dose, no number of divided doses per day, no dose interval and no paediatric maximum are given anywhere in this bundle, and no age band is attached to the 150 mg/kg/day figure. CONCENTRATION: 50 mg/mL is the intravenous reconstitution from the SPC method of administration ('Dissolve 500 mg in 10 ml water for injections'); the intramuscular reconstitution is different (add 1.5 ml water for injections to a 500 mg vial), so this concentration applies to the IV route only. The US source in this bundle is ampicillin WITH SULBACTAM and its 300 mg/kg/day paediatric figure is a combination total (200 mg ampicillin plus 100 mg sulbactam per kg per day) - it has not been used here. Verify the paediatric dose, the dosing interval and any neonatal dose against a children's formulary.

Verify in a children's formulary

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients (eMC §4.3)
  • History of hypersensitivity to beta-lactam antibiotics - e.g. ampicillin, penicillins, cephalosporins (eMC §4.3)
  • Avoid if infectious mononucleosis and/or acute or chronic leukaemia of lymphoid origin are suspected, because of the associated skin rash (eMC §4.4 - a special warning rather than an absolute §4.3 contraindication)

Side effects

  • Hypersensitivity: skin rash, pruritus and urticaria reported occasionally, with a higher incidence in infectious mononucleosis and acute or chronic leukaemia of lymphoid origin; purpura also reported. 'If any hypersensitivity reaction occurs, the treatment should be discontinued' (eMC §4.8)
  • Rarely: erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis; anaphylaxis reported rarely (eMC §4.8, §4.4)
  • Gastrointestinal: nausea, vomiting and diarrhoea; pseudomembranous colitis and haemorrhagic colitis reported rarely (eMC §4.8)
  • Renal: interstitial nephritis can occur rarely (eMC §4.8)
  • Hepatic: hepatitis and cholestatic jaundice reported rarely; moderate and transient increase in transaminases (eMC §4.8)
  • Haematological: transient leucopenia, transient thrombocytopenia and haemolytic anaemia reported rarely; prolongation of bleeding time and prothrombin time also reported rarely (eMC §4.8)
  • Injection-site reactions reported for the related combination product (ampicillin with sulbactam, US label, quoted for context only): pain at IM injection site 16%, pain at IV injection site 3%, thrombophlebitis 3%, phlebitis 1.2%

Monitoring

  • Before starting: 'careful enquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics' (eMC §4.4)
  • Watch for hypersensitivity and anaphylaxis - serious and occasionally fatal reactions have been reported with beta-lactams, more frequently following parenteral therapy (eMC §4.4)
  • Renal function - dosage should be adjusted in renal impairment, with an additional dose after dialysis (eMC §4.2, §4.4)
  • Prolonged use may occasionally result in overgrowth of non-susceptible organisms (eMC §4.4)
  • Watch for diarrhoea - pseudomembranous colitis and haemorrhagic colitis have been reported rarely (eMC §4.8)
  • Urine glucose testing: use enzymatic glucose oxidase methods, because high urinary ampicillin concentrations make false positive readings common with chemical methods (eMC §4.5)
  • Sodium load in patients on a controlled sodium diet: 33.7 mg of sodium per vial (eMC §4.4)
  • Do not mix with an aminoglycoside in the syringe, intravenous fluid container or giving set - loss of aminoglycoside activity can occur (eMC §4.5)

Clinical monograph

How it works

It inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, leading to bacterial lysis.

Prescribing in practice

  • It is contraindicated in patients with penicillin hypersensitivity, who are at risk of anaphylaxis.
  • A maculopapular rash is common if given in glandular fever (infectious mononucleosis) and it should be avoided in this setting.
  • Many common organisms produce beta-lactamases conferring resistance, so therapy should be guided by susceptibility where possible.

Monitoring

Monitor for hypersensitivity reactions and clinical response, and review renal and hepatic function with prolonged or high-exposure treatment.

Counselling the patient

  • Report any rash, swelling or breathing difficulty, which may indicate allergy.
  • Complete the full prescribed course even if you feel better.
  • Tell your prescriber if you have ever reacted to a penicillin.

Evidence & guidelines

Ampicillin and related aminopenicillins are long-established agents with well-defined roles in UK antimicrobial guidance.

Reference: BSAC Endocarditis Guidelines (2012 updated); NICE NG51 (Meningitis); PHE/UKHSA antibiotic guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.